分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

PML targets and resolves structured protein inclusions to mitigate neurodegeneration

Wang Yang, Zhu Jia-Xin, Zhan Fei-Xia, Guo Yinfeng, Xia Yuchen, Liu Jiaqi, Dai Peng, Hu Ying, Chen Yan-Hao, Luan Xing-Hua, Shen Xi-Ya, Cao Yu-Wen, Huang Xiaojun, Zhang Xin, Cao Li, Hou Steven X.

Journal:NATURE CELL BIOLOGY

IF:22.7

DOI:10.1038/s41556-026-01894-z

PMID:41741685

Published:2026-02-25

research field:神经科学蛋白质质量控制分子生物学细胞生物学神经退行性疾病

Abstract

Intranuclear inclusions are defining features of many neurodegenerative diseases, yet their assembly mechanisms and pathological roles remain poorly understood. Here, we investigate polyglycine (polyG) inclusions in neuronal intranuclear inclusion disease (NIID) and show that they recruit intrinsically disordered proteins to form stratified, immobile condensates that disrupt nuclear protein quality control and DNA damage repair. Leveraging their ordered and stepwise assembly, we identify promyelocytic leukaemia protein (PML) as a key factor that actively recognizes and eliminates polyG inclusions through chaperone-mediated disaggregation and proteasome-dependent degradation. Engineered PML variants selectively clear both nuclear and cytoplasmic aggregates, including polyG, polyGA, polyQ, TDP-43 and SOD1. Systemic PML delivery alleviates cognitive and motor deficits in mouse models of NIID and TDP-43 proteinopathy. These findings uncover a conserved spatial organization of nuclear inclusions and establish PML as a therapeutic effector for neurodegenerative diseases linked to protein aggregation.

本文使用的Yeasen产品

购物车
客服
转染试用